Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy-February 2024-www.financetom.com

Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Tharimmune Shares Climb on Positive Feedback From EMA on Potential Pruritus Therapy

Nov 3, 2024 3:02 PM

11:06 AM EDT, 10/30/2024 (MT Newswires) -- Tharimmune ( THAR ) shares climbed by more than 130% in recent Wednesday trading after the company said it received "positive feedback" from the European Medicines Agency about TH104, its candidate to treat moderate-to-severe pruritus in primary biliary cholangitis, or PBC.

The feedback came in a Scientific Advice meeting, the company said, where the agency provided guidance on a planned phase 2 trial to advance TH104.

The agency noted that there was no need to conduct additional animal studies and considered human exposure adequate to move forward, the company added.

Tharimmune ( THAR ) said it plans to start a phase 2 multiple-ascending dose trial in the coming months to evaluate the safety and tolerability of TH104, and expects topline data in 2025.

Price: 4.46, Change: +2.44, Percent Change: +120.79

Previous page： Update: Iridium Communications Shares Rise After Company Swings to Q3 Net Income Next page： Update: Amicus Therapeutics Shares Surge After Settling Patent Suit Against Teva Pharmaceuticals With License Deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Update: Iridium Communications Shares Rise After Company Swings to Q3 Net Income

Oct 17, 2024

11:08 AM EDT, 10/17/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.) Iridium Communications ( IRDM ) shares were up nearly 16% in recent Thursday trading after the company reported Q3 net income of $0.21 per diluted share, swinging from a loss of $0.01 a year earlier. Analysts polled by Capital IQ...

Update: Amicus Therapeutics Shares Surge After Settling Patent Suit Against Teva Pharmaceuticals With License Deal

Oct 17, 2024

11:12 AM EDT, 10/17/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.) Amicus Therapeutics' ( FOLD ) shares were up over 12% in recent trading Thursday after the company said it agreed to settle its patent litigation against Teva Pharmaceuticals (TEVA). Amicus said it agreed to grant Teva a license to market its generic...

Westamerica Bancorporation Q3 Earnings, Revenue Fall

Oct 17, 2024

11:14 AM EDT, 10/17/2024 (MT Newswires) -- Westamerica Bancorporation (WABC) reported Q3 earnings Thursday of $1.31 per diluted share, down from $1.56 a year earlier. Three analysts polled by Capital IQ expected $1.24. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and total noninterest income, was $74.4 million, down from $83.4 million a...

Miata Metals Closes the $7.1-Million Purchase of 79North, Establishes Gold Exploration Portfolio in Suriname

Oct 17, 2024

11:09 AM EDT, 10/17/2024 (MT Newswires) -- Miata Metals ( MMETF ) on Thursday said it closed its acquisition of 79North in a $7.1 million all-share transaction. Miata now holds a 70% interest in the Sela Creek Gold Project, which it can increase to 100%, and a 70% interest in the Nassau gold project, both in Suriname. Miata is in...